Compugen Cuts Q1 Loss Despite No Revenues | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Compugen today reported that it generated no revenues for the first quarter of 2011, compared to $125,000 for the first quarter of 2010.

The Tel Aviv, Israel-based firm, which makes computational biology tools and is developing therapeutics, reported a net loss of $1.9 million, or $.06 per share, for the three-month period ended March 31. For Q1 2010, its net loss was $2.7 million, or $.08 per share.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: RNA-seq, ChIP-seq to determine metformin response; array-based approach to detect protozoa in blood; and more.

Fast Company takes a look at startups in the nutrigenomic space that aim to offer personalized diet advice.

In a glamorous event, the Breakthrough Foundation gave out more than $25 million in prizes to researchers.

Immunotherapy might treat cancer, but it also appears to come with a risk of a number of side effects, the New York Times reports.